Effect of external factors on the curcumin/2-hydroxypropyl-β- cyclodextrin: In vitro and in vivo study

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 73, Issue 1-4, 2012, Pages 423-433

  Ouyang, Hui Zi ^a,b   Fang, Ling ^a   Zhu, Lin ^b   Zhang, Lei ^a   Ren, Xiao Liang ^a   He, Jun ^b   Qi, Ai Di ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Key Laboratory of Traditional Chinese Medicinal Chemistry   (China)

Author keywords

Curcumin; Cyclodextrin; Pharmacokinetics; Phase solubility; Stability

Indexed keywords

EID: 84862611115     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-011-0080-x     Document Type: Article

References (57)

1. CAC Araujo LL Leon 2001 Biological activities of Curcuma longa L Mem. Inst. Oswaldo Cruz 96 723 728 10.1590/S0074-02762001000500026 1:CAS:528:DC%2BD3MXls1Slsr0%3D
2. K Srinivasan 2005 Spices as influencers of body metabolism: an overview of three decades of research Food Res. Int. 38 77 86 10.1016/j.foodres.2004.09. 001 1:CAS:528:DC%2BD2cXpt1Wgtbk%3D
3. RR Tayyem DD Heath WK Al-Delaimy CL Rock 2006 Curcumin content of turmeric and curry powders Nutr. Cancer 55 126 131 10.1207/s15327914nc5502-2 1:CAS:528:DC%2BD28XhtlentLvI
4. BB Aggarwal KB Harikumar 2009 Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases Int. J. Biochem. Cell Biol. 41 40 59 10.1016/j.biocel.2008.06.010 1:CAS:528:DC%2BD1cXhsVWnu73P
5. RA Sharma WP Steward AJ Gescher 2007 Pharmacokinetics and pharmacodynamics of curcumin Adv. Exp. Med. Biol. 595 453 470 10.1007/978-0-387-46401-5-20
6. C Ireson S Orr DJL Jones R Verschoyle CK Lim JL Luo L Howells S Plummer R Jukes M Williams WP Steward A Gescher 2001 Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E-2 production Cancer Res. 61 1058 1064 1:CAS:528: DC%2BD3MXhsFSqsr0%3D
7. G Bar-Sela R Epelbaum M Schaffer 2010 Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications Curr. Med. Chem. 17 190 197 10.2174/092986710790149738 1:CAS:528:DC%2BC3cXhsVSls7k%3D
8. S Somasundaram NA Edmund DT Moore GW Small YY Shi RZ Orlowski 2002 Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer Cancer Res. 62 3868 3875 1:CAS:528:DC%2BD38XltF2ju7g%3D
9. DP Chauhan 2002 Chemotherapeutic potential of curcumin for colorectal cancer Curr. Pharm. Des. 8 1695 1706 10.2174/1381612023394016 1:CAS:528:DC%2BD38XlslKhtr0%3D
10. HHP Cohly S Asad SK Das MF Angel M Rao 2003 Effect of antioxidant (turmeric, turmerin and curcumin) on human immunodeficiency virus Int. J. Mol. Sci. 4 22 33 10.3390/i4020022 1:CAS:528:DC%2BD3sXit12rtrk%3D
11. K Balasubramanyam RA Varier M Altaf V Swaminathan NB Siddappa U Ranga TK Kundu 2004 Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription J. Biol. Chem. 279 51163 51171 10.1074/jbc.M409024200 1:CAS:528:DC%2BD2cXhtVaqsrvE
12. ME Egan M Pearson SA Weiner V Rajendran D Rubin J Glockner-Pagel S Canny K Du GL Lukacs MJ Caplan 2004 Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects Science 304 600 602 10.1126/science.1093941 1:CAS:528:DC%2BD2cXjt1Crsrs%3D
13. P Zeitlin 2004 Can curcumin cure cystic fibrosis? New Engl. J. Med. 351 606 608 10.1056/NEJMcibr041584 1:CAS:528:DC%2BD2cXmtF2qsrk%3D
14. AN Begum MR Jones GP Lim T Morihara P Kim DD Heath CL Rock MA Pruitt FS Yang B Hudspeth SX Hu KF Faull B Teter GM Cole SA Frautschy 2008 Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease Frautschy J. Pharmacol. Exp. Ther. 326 196 208 10.1124/jpet.108.137455 1:CAS:528:DC%2BD1cXotlyltr8%3D
15. MA Ortiz-Ortiz JM Moran LM Ruiz-Mesa M Niso-Santano JM Bravo-SanPedro R Gomez-Sanchez RA Gonzalez-Polo JM Fuentes 2010 Curcumin exposure induces expression of the Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells Neurosci. Lett. 468 120 124 10.1016/j.neulet.2009.10.081 1:CAS:528:DC%2BD1MXhsV2ksb3I
16. P Anand AB Kunnumakkara RA Newman BB Aggarwal 2007 Bioavailability of curcumin: problems and promises Mol. Pharmacol. 4 807 818 10.1021/mp700113r 1:CAS:528:DC%2BD2sXht12gsrnF
17. ME Brewster T Loftsson 2007 Cyclodextrins as pharmaccutical solubilizers Adv. Drug Deliv. Rev. 59 645 666 10.1016/j.addr.2007.05.012 1:CAS:528: DC%2BD2sXpsFGks7g%3D
18. HS Choi A Takahashi T Ooya N Yui 2004 Structural role of guest molecules in rapid and sensitive supramolecular assembling system based on β-cyclodextrin-conjugated poly(epsilon-lysine) Macromolecules 37 10036 10041 10.1021/ma0487610 1:CAS:528:DC%2BD2cXhtVSmu7%2FM
19. ME Davis ME Brewster 2004 Cyclodextrin-based pharmaceutics: past, present and future Nat. Rev. Drug Discov. 3 1023 1035 10.1038/nrd1576 1:CAS:528:DC%2BD2cXhtVarsL3P
20. B Yang LJ Yang J Lin Y Chen Y Liu 2009 Binding behaviors of scutellarin with α-, β-, γ-cyclodextrins and their derivatives J. Incl. Phenom. Macrocycl. Chem. 64 149 155 10.1007/s10847-009-9547-4 1:CAS:528:DC%2BD1MXlslWntLg%3D
21. Y Liu GS Chen Y Chen N Zhang J Chen YL Zhao 2006 Bundle-shaped cyclodextrin-Tb nano-supramolecular assembly mediated by C-60 Nano Lett. 6 2196 2200 10.1021/nl061393o 1:CAS:528:DC%2BD28XpvVSmtrc%3D
22. T Loftsson D Duchene 2007 Cyclodextrins and their pharmaceutical applications Int. J. Pharm. 329 1 11 10.1016/j.ijpharm.2006.10.044 1:CAS:528:DC%2BD28XhtlCmtLrF
23. T Loftsson D Hreinsdottir M Másson 2005 Evaluation of cyclodextrin solubilization of drugs Int. J. Pharm. 302 18 28 10.1016/j.ijpharm.2005.05.042 1:CAS:528:DC%2BD2MXpvVWju7w%3D
24. M Agueros L Ruiz-Gaton C Vauthier K Bouchemal S Espuelas G Ponchel JM Irache 2009 Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel Eur. J. Pharm. Sci. 38 405 413 10.1016/j.ejps.2009.09.010 1:STN:280:DC%2BD1MnpslKrtQ%3D%3D
25. A Muraoka T Tokumura Y Machida 2004 Evaluation of the bioavailability of flurbiprofen and its β-cyclodextrin inclusion complex in four different doses upon oral administration to rats Eur. J. Pharm. Biopharm. 58 667 671 10.1016/j.ejpb.2004.03.030 1:CAS:528:DC%2BD2cXnvFagurY%3D
26. CM Buchanan NL Buchanan KJ Edgar JL Little MG Ramsey KM Ruble VJ Wacher MF Wernpe 2008 Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-β-cyclodextrin formulations Biomacromolecules 9 305 313 10.1021/bm700827h 1:CAS:528:DC%2BD2sXhsVWgur7I
27. B Cappello C Carmignani M Iervolino MI La Rotonda MF Saettone 2001 Solubilization of tropicamide by hydroxypropyl-β-cyclodextrin and water-soluble polymers: in vitro/in vivo studies Int. J. Pharm. 213 75 81 10.1016/S0378-5173(00)00648-7 1:CAS:528:DC%2BD3MXmvFKqsw%3D%3D
28. T Loftsson ME Brewster 1996 Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization J. Pharm. Sci. 85 1017 1025 10.1021/js950534b 1:CAS:528:DyaK28XlsFSrsr4%3D
29. AB Hegge RB Schuller S Kristensen HH Tønnesen 2008 In vitro release of curcumin from vehicles containing alginate and cyclodextrin. Studies of curcumin and curcuminoides. XXXIII Pharmazie 63 585 592 1:CAS:528: DC%2BD1cXhtVSrsbbL
30. VA Marcolino GM Zanin LR Durrant MDT Benassi G Matioli 2011 Interaction of curcumin and bixin with β-cyclodextrin: complexation methods, stability, and applications in food J. Agric. Food Chem. 59 7 3348 3357 10.1021/jf104223k 1:CAS:528:DC%2BC3MXivVSitLY%3D
31. B Tang L Ma HY Wang GY Zhang 2002 Study on the supramolecular interaction of curcumin and β-cyclodextrin by spectrophotometry and its analytical application J. Agric. Food Chem. 50 1355 1361 10.1021/jf0111965 1:CAS:528:DC%2BD38XhtVKitL4%3D
32. AD Qi L Li Y Liu 2003 The binding ability and inclusion complexation behavior of curcumin with natural α-, β-, γ-cyclodextrins and organoselenium-bridged bis (β-cyclodextrin)s J. Chin. Pharm. Sci. 12 1 15 20 1:CAS:528:DC%2BD3sXjsFykt70%3D
33. R Singh HH Tønnesen SB Vogensen T Loftsson M Másson 2010 Studies of curcumin and curcuminoids. XXXVI. The stoichiometry and complexation constants of cyclodextrin complexes as determined by the phase-solubility method and UV-Vis titration J. Incl. Phenom. Macrocycl. Chem. 66 335 348 10.1007/s10847-009-9651-5 1:CAS:528:DC%2BC3cXjt1KisLg%3D
34. S Swaroop B Mishra KI Priyadarsini 2007 Studies on β-cyclodextrin inclusion complex of curcumin Proc. Natl. Acad. Sci. India B Biol. Sci. 77 3 205 211
35. KN Baglole PG Boland BD Wagner 2005 Fluorescence enhancement of curcumin upon inclusion into parent and modified cyclodextrins J. Photochem. Photobiol. A. 173 230 237 10.1016/j.jphotochem.2005.04.002 1:CAS:528:DC%2BD2MXlvV2msLo%3D
36. HH Tønnesen M Másson T Loftsson 2002 Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability Int. J. Pharm. 244 127 135 10.1016/S0378-5173(02)00323-X
37. MA Tomren M Másson T Loftsson HH Tønnesen 2007 Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin Int. J. Pharm. 338 27 34 10.1016/j.ijpharm.2007.01.013 1:CAS:528:DC%2BD2sXlslWgs74%3D
38. VR Yadav S Suresh K Devi S Yadav 2009 Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model AAPS PharmSciTech 10 3 752 762 10.1208/s12249-009-9264-8 1:CAS:528:DC%2BC3cXosVansL8%3D
39. MM Yallapu M Jaggi SC Chauhan 2010 β-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells Colloids Surf. B Biointerfaces 79 1 113 125 10.1016/j.colsurfb.2010.03.039 1:CAS:528:DC%2BC3cXmsVOgu7c%3D
40. S Gould RC Scott 2005 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review Food Chem. Toxicol. 43 1451 1459 10.1016/j.fct.2005.03.007 1:CAS:528:DC%2BD2MXmt1eiu78%3D
41. VJ Stella VM Rao EA Zannou V Zia 1999 Mechanisms of drug release from cyclodextrin complexes Adv. Drug Deliv. Rev. 36 3 16 10.1016/S0169-409X(98) 00052-0 1:CAS:528:DyaK1MXksFegtg%3D%3D
42. R Sanghvi E Mogalian SG Machatha R Narazaki KL Karlage P Jain SE Tabibi E Glaze PB Myrdal SH Yalkowsky 2009 Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor J. Pharm. Sci. 98 205 214 10.1002/jps.21421 1:CAS:528:DC%2BD1MXns1WjsA%3D%3D
43. S Tommasini ML Calabro D Raneri P Ficarra R Ficarra 2004 Combined effect of pH and polysorbates with cyclodextrins on solubilization of naringenin J. Pharm. Biomed. Anal. 36 327 333 10.1016/j.jpba.2004.06.013 1:CAS:528: DC%2BD2cXovV2htLc%3D
44. SM Pathak P Musmade S Dengle A Karthik K Bhat N Udupa 2010 Enhanced oral absorption of saquinavir with methyl-β-cyclodextrin-preparation and in vitro and in vivo evaluation Eur. J. Pharm. Sci. 41 440 451 10.1016/j.ejps.2010. 07.013 1:CAS:528:DC%2BC3cXht1Gjt7nM
45. C Holvoet J Plaizier-Vercammen Y Vander Heyden M Gabriels F Camu 2003 Preparation and in vitro release rate of fentanyl-cyclodextrin complexes for prolonged action in epidural analgesia Int. J. Pharm. 265 13 26 10.1016/S0378-5173(03)00368-5 1:CAS:528:DC%2BD3sXns1SjtL0%3D
46. ZM Wu IG Tucker M Razzak K McSporran NJ Medlicott 2010 Tissue compatibility and pharmacokinetics of three potential subcutaneous injectables for low-pH drug solutions J. Pharm. Pharmacol. 62 873 882 10.1111/j.2042-7158. 2010.01137.x 1:CAS:528:DC%2BC3cXpt1yit7c%3D
47. HK Han HK Choi 2007 Improved absorption of meloxicam via salt formation with ethanolamines Eur. J. Pharm. Biopharm. 65 99 103 10.1016/j.ejpb.2006.07.003 1:CAS:528:DC%2BD28Xht1KlsLzJ
48. N Jerry Y Anitha CP Sharma P Sony 2001 In vivo absorption studies of insulin from an oral delivery system Drug Deliv. 8 19 23 10.1080/ 107175401300002711 1:CAS:528:DC%2BD3MXhs1Oitbg%3D
49. T Higuchi KA Connors 1965 Phase-solubility techniques Adv. Anal. Chem. Instrum. 4 117 212 1:CAS:528:DyaF2MXktlGitrg%3D
50. T Loftsson M Másson ME Brewster 2004 Self-association of cyclodextrins and cyclodextrin complexes J. Pharm. Sci. 93 1091 1099 10.1002/jps.20047 1:CAS:528:DC%2BD2cXjsFKisLo%3D
51. S Tommasini D Raneri R Ficarra ML Calabro R Stancanelli P Ficarra 2004 Improvement in solubility and dissolution rate of flavonoids by complexation with β-cyclodextrin J. Pharm. Biomed. Anal. 35 379 387 10.1016/S0731- 7085(03)00647-2 1:CAS:528:DC%2BD2cXivVWrtLw%3D
52. YJ Wang MH Pan AL Cheng LI Lin YS Ho CY Hsieh JK Lin 1997 Stability of curcumin in buffer solutions and characterization of its degradation products J. Pharm. Biomed. Anal. 15 1867 1876 10.1016/S0731-7085(96)02024-9 1:CAS:528:DyaK2sXlvVejtbo%3D
53. SG Feng GY Qin HX Liu ZH Jiang JM Liang F Qiu 2009 Isolation and identification of degradation products of curcumin and study of stability of curcumin J. Shenyang Pharm. Univ. 26 5 361 365 1:CAS:528:DC%2BD1MXnslWgtrs%3D
54. HH Tønnesen J Karlsen 1985 Studies on curcumin and curcuminoids. V. Alkaline degradation of curcumin Z. Lebensm. Unters. Forsch. 180 132 134 10.1007/BF01042637
55. GM Holder JL Plummer AJ Ryan 1978 The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat Xenobiotica 8 12 761 768 10.3109/00498257809069589 1:CAS:528: DyaE1MXks1yhs7k%3D
56. V Ravindranath N Chandrasekhara 1980 Absorption and tissue distribution of curcumin in rats Toxicology 16 3 259 265 10.1016/0300-483X(80)90122-5 1:CAS:528:DyaL3cXmtFKhsL4%3D
57. R Arun CK Ashok Kumar VVNSS Sravanthi 2008 Cyclodextrins as drug carrier molecule: a review Sci. Pharm. 76 567 598 10.3797/scipharm.0808-05